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and T cell progenitors) in all investigated
sites, namely the dorsal aorta, placenta,
and yolk sac, although this latter also con-
tains the vitellin vessels. Assuming that
the absence of circulation and conse-
quent hypoxia does not influence the
site and timing of hematopoietic cell gen-
eration, this study indicates that multiline-
age hematopoietic progenitors can origi-
nate independently from the dorsal
aorta, the placenta, and the territory com-
prising the yolk sac and vitellin arteries.
Only a limited fraction of the hemato-
poietic cells generated in the embryo
will become HSCs. Most progenitors are
rather restricted in their differentiation
potential and will either engage in the
erythrocyte or the myelo-monocytic line-
ages. A minority of cells are lympho-
myeloid progenitors and when placed
under the appropriate conditions will dif-
ferentiate into all hematopoietic lineages.
Of these populations, the first to appear
only display reconstitution capacity if in-
jected in newborn animals or in severely
immunocompromised recipients. In more
developed embryos, robust long-term
reconstituting multipotent cells can be
isolated. The unequivocal identification
of a HSC still requires demonstration of
multilineage potential at the single-cell
level as well as the capacity to reconsti-
tute the entire hematopoietic compart-
ment upon transfer. In vivo protocols
have been described that provide ade-
quate conditions for cells isolated at the
embryonic stages studied here to provide
long-term hematopoietic contribution
(Yoder et al., 1997; Cumano et al., 2001).
They involve either injection of cells in the
liver of newborn mice or intravenous
injection in B/T/NK-deficient mice. The
in vivo reconstitution capacity of the cells
detected in this study has not been
assessed, and therefore their HSC nature
has yet to be fully determined.
An expectation of this experimental
system is that, since cells are actively
dividing, in the absence of circulation the
newly generated hematopoietic cells
might accumulate in the placenta. Due
to the early lethality experienced by the
mutant mice used in this system, the tim-
ing of analysis is obviously constrained,
and the number of embryos obtained is
severely limiting. Nevertheless, the au-
thors endeavored to quantify cells present
in sections of the placenta of normal and
Ncx1 mutants. Mutant mice exhibit 5-
fold less hematopoietic progenitors than
the wild-type. This result indicates that
probably only a small fraction of hemato-
poietc multipotent progenitors normally
detected here are of placental origin and
that the majority of cells observed in pre-
vious studies likely originate elsewhere.
The picture that emerges from this work
is that hematopoietic progenitors that
are generated during a short window in
gestation do so at multiple sites, including
the large vessels (aorta, vitellin vessels) or
vascular networks (the placenta and yolk
sac) in close connection to the endothelial
cell compartment.
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Stem cell-based regeneration depends partly on the delivery of stem cells to the damaged area. Recently in
Nature Medicine, Sackstein et al. (2008) report that ex vivo fucosylation of surface CD44 promoted efficient
adhesive interactions of manipulated mesenchymal stem cells with marrow vasculature and subsequent
homing to endosteal surfaces.Multipotent stem cells, whether somatic
or embryonic stem cell-derived, possess
a great capacity for tissue regeneration.
In clinical settings, the optimal route for
administration of stem cells depends on
the anatomy and the extent of damage
of the involved tissue or organ, offering a198 Cell Stem Cell 2, March 2008 ª2008 Elschoice between two approaches: direct
local or intralesional implantation versus
systemic intravascular administration. Al-
though feasible for tissues with defined
anatomic boundaries, local implantation
is invasive, has associated procedure-re-
lated costs, and could result in significantevier Inc.morbidity. Moreover, this approach could
disrupt a highly complex and delicate
structure of the local regulatory microen-
vironment, i.e., the niche, causing addi-
tional traumatic injury and inflammation.
Another limitation for the local administra-
tion of stem cells is the multifocality of
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rologic diseases (e.g., multiple sclerosis
and amyotrophic lateral sclerosis), mus-
cular diseases (e.g., Duchenne’s muscu-
lar dystrophy), and skeletal diseases (e.g.,
osteoporosis and osteogenesis imper-
fecta). Thus, stem cell-based therapy of
‘‘systemic’’ disorders mandates vascular
delivery. However, this approach is lim-
ited by the difficulty of ensuring that suf-
ficient numbers of reconstituting cells
reach the damaged areas in cases of in-
effective stem cell homing. Fulfilling the
promise of regenerative medicine, there-
fore, critically depends first on identifying
the range of molecules that mediate
organ-specific stem cell homing and
second on manipulating their activity (for
review, see Mooney and Vandenburgh
[2008], this issue of Cell Stem Cell).
The recent study by Sackstein and col-
leagues (Sackstein et al., 2008) reports
new insights into the function of CD44
as a homing molecule for bone marrow-
derived mesenchymal stem cells (MSC).
While homing of cells involves a cascade
of events, the critical initial step is a pro-
cess known as ‘‘rolling,’’ whereby migrat-
ing cells engage in shear-resistant, low-af-
finity interactionswith vascular endothelial
cells (Butcher, 1991). The process of roll-
ing is essential for cell homing since it
selectively slows down subsets of circu-
lating cells (out of the larger population
of all fast-flowing cells), allowing their
subsequent endothelial adhesion and
transmigration under conditions of phy-
siological shear stress.Whilemanymech-
anism(s) regulating homing of nonhema-
topoietic stem cells remain illusive,
Sackstein and colleagues addressed this
key aspect of MSC biology and demon-
strated that a distinct glycoform of CD44
mediates trafficking of human MSCs to
bone through interactions with E-selectin,
which is constitutively present on marrow
vasculature.
CD44 adhesion molecules represent
a large family of transmembrane glyco-
proteins. Alternatively spliced additional
exons may be inserted into the extracel-
lular domain of CD44, determining the
structure and differential function of the
multiple CD44 splice variants (Khaldoya-
nidi et al., 2002). Further complexity of
this family of adhesion molecules is deter-
mined by the fact that the extracellular
domain of CD44 also contains N- and
O-linked glycosylation sites, yielding vari-Figure 1. Schematic Representation of CD44-Ligand Interactions during MSC Homing
Following ex vivo fucosylation, MSCs express high levels of HCELL, the sialofucosylated glycoform of
CD44. Interactions between HCELL and E-selectin, expressed on the surface of bone marrow-endothelial
cells, result in rolling of MSCs. Due to the transient nature of the ex vivo-induced fucosylation, HCELL
disappears, leading to conformational modifications of CD44 and changed ligand-binding affinity. This
contributes to the ability of migrated MSCs to recognize other CD44 ligands including hyaluronan (HA),
FGF, and osteopontin and to respond to the local signals within the microenvironment.ous glycoforms of CD44. Importantly, the
ligand-binding affinity of CD44 depends
on its glycosylation pattern (Katoh et al.,
1995). Previous studies performed in
Sackstein’s laboratory demonstrate that
a sialofucosylated glycoform of CD44
expressed on human hematopoietic cells
and called hematopoietic cell E-/L-selec-
tin ligand (HCELL) was a potent E-selectin
ligand (Dimitroff et al., 2001). In the current
study, the investigators found that human
MSCs display the standard (i.e., not alter-
natively spliced) form of CD44, which con-
tains a-2,3-sialylated, but not a-1,3 fuco-
sylated, glycans. To generate HCELL,
Sackstein and colleagues formulated a
novel in vitro protocol containing fuco-
syltransferase VI (FTVI), fucose residues,
and associated buffers to enforce stereo-
specific fucosylation of CD44 without af-
fecting viability and stemness of MSCs.
HCELL expression was induced tran-
siently (high levels sustained for only 24 hr),
conferring robust rolling of MSCs on vas-
cular E-selectin in vitro. While CD44 has
multiple ligands, this receptor/ligand
specificity of CD44—engineered in vitro—
may offer an opportunity to direct the mi-
gration of stem cells to one organ versus
another. Given that the vascular pheno-Cell Stemtype of individual tissues and organs is
highly specialized (Ruoslahti and Rajotte,
2000), it will be important to determine
which vascular adhesion molecules, ex-
pressed alone or in combination, contrib-
ute to the process of homing of hemato-
poietic and nonhematopoietic stem cells
to a particular organ. If cell surface mole-
cules expressed on organ-specific endo-
thelium contribute to stem cell-endothelial
cell adhesive interactions, the manipula-
tion of these ‘‘homing signatures’’ may
allow a more precise targeting of stem
cells, directing them to the damaged areas
to the exclusion of undesired organs.
Importantly, the in vivo studies of Sack-
stein and colleagues demonstrated that
transient expression of HCELL was suffi-
cient for homing of intravenously injected
human MSCs to bone in NOD/SCID mice.
HCELLexpressionwasnotassociatedwith
cell ‘‘trapping’’ or ‘‘arrest’’ on the marrow
sinusoids, as humanMSCs transmigrated,
infiltrated marrow parenchyma, and inte-
grated into the local microenvironment.
The temporary expression of HCELL re-
presents a great advantage of this novel
glycan engineering technology over other
methods involving gene transfection and
accompanying permanent expression ofCell 2, March 2008 ª2008 Elsevier Inc. 199
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tact with the endothelium, the interactions
between HCELL and E-selectin are no lon-
ger required. The reversion to the native
CD44 structure is advantageous, as glyco-
sylationmaynegatively impact the ability of
CD44 to recognize hyaluronan (HA) (Katoh
et al., 1995), one of the important compo-
nents of the microenvironment in bone
marrow (Khaldoyanidi et al., 1999). In ad-
dition, CD44 binds to several molecules
besides HA, including osteopontin and
FGF (Ponta et al., 1998), which may be
important for determining the behavior of
MSCs. Thus, migrated MSCs may engage
in appropriate CD44-mediated interac-
tions within the local bone marrow micro-
environment (Figure 1).
The concept of the hematopoietic stem
cell (HSC) niche was proposed three de-
cades ago (Schofield, 1978), and distinct
lines of evidence point to roles for osteo-
blasts, stromal fibroblast-like cells, or en-
dothelial cells in the localization and/or
regulation of HSCs. Most likely, all these
and additional cell types, including bone
marrow-resident macrophages, contrib-
ute to thedelicate andwell-tunedstructure
and function of the HSC niche. However,
whether there are distinct or overlapping
niches for HSC and MSC populations re-200 Cell Stem Cell 2, March 2008 ª2008 Elsmains open to question. Regardless, there
arenodoubts that the localmilieu—normal
or diseased—directly influences the hom-
ing-supportive function of the local endo-
thelium. This is well illustrated by one of
the most-studied examples—inflamma-
tion. However, it remains to be defined
how a variety of other pathological condi-
tions affect the microenvironment in the
involved organs and how these disease-
induced changes influence the ability of
both local and distant endothelial cells to
support homing of transplanted stem cells.
Knowledge of the disease-specific differ-
ences in mechanismsmediating stem cell-
endothelial cell interactions will provide a
basis for future patient-specific therapeutic
approaches in regenerative medicine.
Taken together, the elegant work pub-
lished by Sackstein and colleagues
(Sackstein et al., 2008) provides compel-
ling evidence that ex vivo chemical engi-
neering of the glycosylation to create
a distinct homing molecule can repro-
gram the migratory behavior of infused
stem cells in vivo. Since E-selectin ex-
pression is induced within endothelial
beds at all sites of tissue injury and be-
cause CD44 is expressed at high levels
on most stem cells, strategies to ‘‘custom
modify’’ CD44 glycans to create HCELLevier Inc.could be exploited to control stem cell tis-
sue tropism. Further development of this
exciting technology and other methodolo-
gies that allow manipulation of particular
subsets of homing molecules is pivotal
for refining organ-specific homing and
stem cell-based tissue regeneration.
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